Results 1 to 10 of about 8,267,805 (249)

Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening [PDF]

Journal of Men's Health
This study aimed to investigate the optimal screening interval of a prostate specific antigen (PSA) screening program for men aged 40–70 with a baseline PSA 10 ng/mL, or 4–10 ng/mL (gray area) and f/t PSA
Yu Chen, Gansheng Xie, Gang Li, Yu Li
doaj   +1 more source

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer

Cancer Management and Research
Yeasin Ahamed,1,2 Lichao Wu,1 Shantanu Baral,1 Ashab Uddin Al-Raiyan,1 Weigui Sun1,2 1Department of Urology Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Clinical Medical College ...
Ahamed Y, Wu L, Baral S, Al-Raiyan AU, Sun W   +4 more
doaj  

Comparison of the Diagnostic Performance of Multiparametric Prostate Magnetic Resonance Imaging Results with Classical Parameters for Prostate Carcinoma in Gray Zone Patients

Journal of Urological Surgery
Objective: To compare the diagnostic value of prostate imaging-reporting and data system (mpMRI) version 2.0 with classical parameters for prostate cancer detection in gray zone patients with ultrasonography-guided prostate biopsy as a reference point ...
Coşkun Bostancı, Demirhan Örsan Demir
doaj   +1 more source

Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

BMC Urology
Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes.
Juan Manuel Palacios, Pratiksha Kapse, Vanessa Cortes, Marcio Augusto Averbeck, Alberto Budia Alba, Suryakant Somvanshi, Danilo Souza Lima da Costa Cruz, Fiona Pereira   +7 more
doaj   +1 more source

Epidemiological Study of Patients with Prostate Cancer in South of Iraq

مجلة علوم ذي قار, 2019
The present study was designed to investigate some epidemiological and serological study, in a sample of Thi-Qar, Basarh, Missan provinces south of Iraq.
Manal Badi Salih Al-Tmemi
doaj  

Neuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report

IJU Case Reports
Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate ...
Yoshihiro Nakagami, Shintaro Ohnuma, Masashi Tamaoka, Tatsuki Inoue, Motoki Yamagishi, Kazuhiko Oshinomi, Masakazu Nagata, Yasuyuki Oohira, Toshiko Yamochi, Takashi Fukagai   +9 more
doaj   +1 more source

Diagnostic Values of Serum Total Prostate-Specific Antigen for Detection of Breast Masses Nature in 20-75-Year-Old Women with Breast Mass

مجله دانشکده پزشکی اصفهان, 2017
Background: Previous studies had shown that patients with breast cancer have a high level of prostate-specific antigen (PSA). But there was not any study about the role of prostate-specific antigen in detection of breast cancer.
Gholamreza Mohajeri, Mohamadsaleh Jafarpisheh, Hamidreza Kaviani   +2 more
doaj  

The performance of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction. [PDF]

BJUI Compass
Saliba S, Kjellman A, Thor A, Norming U, Lantz A, Gustafsson O, Lundgren PO.   +6 more
europepmc   +1 more source

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer. [PDF]

Signal Transduct Target Ther
Roviello G, Santoni M, Antonuzzo L.
europepmc   +1 more source

Prostate-specific antigen clearance after surgery for benign prostate enlargement in a cohort with median prostate-specific antigen greater than 4ng/ml. [PDF]

BMC Urol
Nwosu EO, Mbadiwe OM, Nwosu NI, Nnabugwu CA, Anakebe IN, Osaat IS, Nnabugwu II.   +6 more
europepmc   +1 more source